Europe could lose out to the US and Asia for new investments in biopharmaceutical research and production, according to a new study by consultants Charles River Associates (CRA) which urges more collaboration between industry and policy leaders to boost competitiveness.
The study, called ‘Factors Affecting the Location of Biopharmaceutical Investments and Implications for European Policy Priorities’, shows the industry’s declining competitiveness in Europe, with the global share of research and development investments, clinical trials and manufacturing output all waning. However, the study, for EFPIA, the representative organisation for Europe’s biopharmaceutical industry, finds that a key driver of most new investments is the location and performance of existing research and development or manufacturing footprint.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
